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ABSTRACT
Micro RNA are small single stranded RNA that regulate the expression of various
genes. MiRNA guide the mRNA disintegrating RISC complex to the complimentary
sequence in the target mRNA. Each micro RNA has multiple targets and can play a
different biological role depending on the population of targets at the particular stage of
the cell or a physiological state. Several miRNA show elevated or decreased levels of
expression in various cancers because of their role in tumor initiation and progression.
MiRNA belonging to mir148/152 family are examples of such MicroRNA. This family
includes miR148a, miR148b and miR152. MiR148a and miR152 are down-regulated in
various cancers while there is no significant change in the expression of miR148b. Prior
studies indicate a role for miR152 and mir148a in suppressing tumor growth in various
cancers. However, the mechanism of action and targets remain to be identified.
Interestingly, miR148b and miR152 are encoded within the first intron of COPZ1
and COPZ2 genes respectively. This study started with the understanding of the role of
miR152 in cancer progression. COPZ2 gene expression is lower in malignant tissues of
different tumor types when compared to benign tumors suggesting a similar expression
pattern for miR152. We have identified several candidate targets for miR152 in the TGFβ pathway including DNMT1, LTBP1, SERPINE1 and the Rho GEF -LARG. This data
led to the hypothesis that miR152 expression correlates with tumor progression and
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that miR152 suppresses epithelial to mesenchymal transition (EMT) and EMT related
events through regulation of specific EMT mediators and effectors. However, all the
members belonging to this family have the same seed sequence that binds to the target
genes, suggesting that they play similar roles and have common targets.
In this thesis, I have verified LTBP1 and PAI1 as novel, common targets for the
miR148/152 family. Additionally, reintroduction of these microRNA into prostate cancer
cell lines can decrease the migratory capabilities and increase the adhesive characteristics.
This biological role of these miRNA can be exploited in the form of replacement miRNA
in cancer therapy.
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CHAPTER 1
INTRODUCTION

Cancer is a complex disease that is characterized by uncontrolled cellular
proliferation, unlimited replicative potential, resistance to apoptosis and invasive
capabilities.[1, 2] It is the leading cause of death in the United States of America, next only
to heart disease, claiming more than half a million lives each year [3]. Cancer is a multistep
process in which cells acquire a series of mutations which cause uncontrolled cell growth
resulting in the formation of a tumor[2]. Eventually, these cancerous tumors undergo
metastasis, a process during which some cells break away from the tumor and invade other
parts of the body[4]. The initiation of cancer is associated with many genetic and epigenetic
alterations which accumulate over time and drive the advancement from normal cell to a
malignant phenotype.[2, 5] This facilitates changes in the expression levels of the genes
that are part of important regulatory pathways in place to prevent the transformation of a
normal cell into a malignant phenotype. Gene expression can be altered by many
mechanisms that cause transcriptional or translational regulation. Post transcriptional or
translational repression by micro RNA is one such mechanism, which is being extensively
studied due to its emerging role in cancer maintenance and progression.
1.1 Epithelial to Mesenchymal Transition
Cancers of the epithelial tissue like breast and prostate are the most common forms of
cancer observed in the clinic. In majority of the cases, cancers of epithelial tissue are not
1

life threatening and surgical removal of the tissue in an early stage can often cure the
cancer. When the cancer metastasizes, it leads to poor prognosis, often resulting in death,
as it disrupts vital organs and tissues like liver, lungs, brain and bone marrow. Therefore,
it is important to understand the progression of metastasis to prevent and treat invasive
malignancies.
Epithelial to Mesenchymal Transition (EMT) is the process by which epithelial
cells morph into mesenchymal cells due to loss of polarity and cell-cell adhesion, and gain
migratory and invasive properties [6]. While EMT is an important program that is required
for embryonic development, wound healing and tissue regeneration, it plays a more
ominous role in cancer progression, where EMT is associated with the conversion of
localized, early tumors to invasive malignancies [7, 8]. EMT is initiated by a number of
biochemical changes in the polarized epithelial cells that are attached to the basement
membrane via its basal surface[9]. This results in the alteration to mesenchymal phenotype
with enhanced migratory capabilities, invasiveness, increased resistance to apoptosis, and
elevated levels of ECM components like fibronectin [10]. Degradation of underlying
basement membrane and the migration of a mesenchymal cell from the epithelial layer in
which it originated marks the completion of EMT [10].
Many molecular processes are involved in this process; activation of transcription
factors, expression of specific cell-surface proteins, production of ECM-degrading
enzymes, reorganization of cytoskeletal proteins, and changes in the expression of specific
microRNAs [11]. While some transcription factors, cell surface proteins and enzymes have
been extensive studied and used as biomarkers to assess the stage of EMT, new
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components, like certain micro RNA, that can either hinder or facilitate the process of EMT
are being discovered and studied every day.
1.2 Micro RNA
Micro RNA are short, single-stranded non-coding RNA, which are about 19-24
nucleotides in length. The main known function of micro RNAs is the down-regulation of
target gene expression by translational repression or degradation of mRNAs upon binding
to the consensus sequence on the target mRNA [12, 13]. Every miRNA can potentially
regulate the expression of numerous protein-coding genes and ~30% genes are regulated
by microRNAs [14]. Even though more than a 1000 microRNAs are expressed in human
cells, not all of them are equally important. High throughput screenings of diverse systems
have identified certain miRNAs as principal regulators of major cell functions in various
physiological (cell cycle, differentiation, development, and metabolism) [15-17] and
pathophysiological (immune and neurodegenerative disorders, diabetes and cancer) [18,
19] settings.
1.2.1 Biogenesis
Genes coding for the miRNA are evolutionarily conserved and can be located in
the introns or exons of protein coding genes (70%) or the intergenic regions (30%)[20, 21].
MiRNA biogenesis and maturation is compartmentalized between the nucleus and
cytoplasm[22]. MiRNA genes are transcribed by RNA polymerase II to generate long
primary transcripts called pri-miRNAs [23]. Intronic miRNAs or Mirtrons are derived from
splicing of host gene’s mRNA or by cropping during transcription [24, 25]. Drosha, an
RNase III–type endonuclease, processes the pri-miRNAs to hair-pin pre-miRNA,
approximately 70 nucleotides in length [26]. The pre-miRNA hairpin is then exported from
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the nucleus into the cytoplasm, where it is processed by another endoribonuclease, Dicer,
into the mature double stranded, but unstable 19-25 nucleotide (miRNA) [27, 28].
Depending on the stability, one of the two strands in the duplex is incorporated into the
RNA-induced silencing complex (RISC), a multiple-protein nuclease complex [29]. The
incorporated strand is called the guide strand and the other strand is called the passenger
strand [28].
1.2.2 Mechanism of Gene Regulation by miRNA
The approximately 6 nucleotide long sequence 5’ end of the miRNA, called the
seed sequence, has a complementary sequence on the mRNA[30]. Once incorporated into
a RISC, the miRNA guides the entire RISC complex to the target mRNA by imperfect
pairing, i.e., they are exactly not complementary[29]. It can then regulate the target genes
by degradation of the mRNA through direct cleavage or by inhibiting protein synthesis by
inhibition of translation initiation or elongation[31]. Putative targets of a miRNA can be
computationally predicted by matching seed sequences of miRNAs to target mRNAs.
1.2.3 MiRNA and cancer
A number of miRNAs have been shown to be deregulated in cancer [15, 18, 32-35]. The
deregulation of miRNAs can be a result of deregulation of upstream regulators of the
miRNAs that has a direct result of changing the expression of their target proteins. As a
result, important pathways that are in place to prevent cancer progression can be
deregulated. An miRNA expression profile or signature can be attributed to certain
malignancies and can also be used for diagnosis and to predict the outcome of the disease
[36-38]. Two broad classes of genes, oncogenes and tumor-suppressor genes play an
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important role in the induction and progression of cancer. MiRNA can also be grouped in
these two categories, based on their targets and their expression profiles.
1.3 MiR148/152 family
MiR148/152 family comprises of three micro RNAs; miR148a, miR148b and
miR152. All three micro RNA have the same seed sequence and have different bases in
three positions; 9, 10 and 20. MiR148/152 family members have been studied individually,
and in some cases miR148a and miR152 have been studied together and it has been shown
that MiR148a and miR152 are down regulated in a number of cancers [39-45] and have
also been known to play a role in immune response[46]. The most important targets that
have been validated for miR148a and miR152 are DNA methylases, DNMT1 and
DNMT3b. This has an important effect on global methylation that can silence non-target
genes like E-cadherin (CDH1) and GSTP1 [40, 41, 44, 47, 48].
1.3.1 MiR148a
MiR-148a is the most comprehensively studied of the three miRNA belonging to
this family. The gene coding for miR148a is intergeneic and is present on chromosome
7[49]. It has been identified as a tumor suppressor miRNA due to its targets and the
observation that it is downregulated in multiple cancers like prostate, breast colorectal and
gastric cancers[42-45, 50, 51]. DNMT1, DNMT 3b, CDC25B, MSK1, Bcl-2, IGF-IR,
IRS1, ERBB3, TGIF2, PXR, CAND1, p27, HLA-C, ACVR1, HLA-G, WNT10B, PTEN,
and ROCK1 are some of the validated targets of miR148a, illustrating its role in various
molecular mechanisms like cell growth and proliferation, migration, invasion, apoptosis,
cell cycle progression, etc. [39, 42, 48-60]. Its function in normal tissue has been examined
but not extensively. miR148a expression is lower in mesenchymal stem cells when
5

compared to the embryonic stem cells[54]. It is most abundant in the liver tissue[61] and it
has been shown that miR-148a abrogates Met/Snail signaling in metastatic hepatocellular
carcinoma by downregulating Met, thereby having a weakening effect on the EMT
program[62].
1.3.2 MiR148b
MiR148 is an intronic miRNA with the gene being encoded within the first intron
of COPZ1 gene on chromosome 12[49]. Is has been shown to be downregulated in some
liver cancer cell lines, oral, pancreatic, colon and gastrointestinal cancers [63-67], while it
has been shown to be unchanged or upregulated in breast and prostate cancers [68, 69]. It
has been speculated that the presence of the miRNA within the intron of COPZ1 is
responsible for its positive expression in some cancers despite having the same seed
sequence as tumor suppressor miRNA (miR148 and miR152). CCKBR and CCK2R, which
are involved in cell proliferation have been validated as targets in gastric and colorectal
cancers respectively, and MCL1 is another probable target [49, 67, 70].
1.3.3 MiR152
MiR152 is also an intronic miRNA and the gene is encoded within the first intron
on COPZ2 gene on chromosome 17. COPZ2 gene encodes for a coatomer protein complex
subunit ζ2 and is not a tumor suppressor, but MiR152 has been shown to be downregulated
along with its host gene, COPZ2, in breast and prostate cancers[69]. It has been perceived
that COPZ2 is downregulated due to the presence of gene for miR152 in its intron. MiR152
is also downregulated in ovarian, gastric, colorectal and endometrial cancers [40, 47, 71].
CSF1, E2F3, MET, Rictor and MLH1 have been validated as targets in at least one cancer
6

type. By downregulating these targets, miR152 plays an important role in cell growth,
motility and adhesion [47].
1.4 Previous Studies and Objective of the Research
The study of this family of miRNA did not start with micro RNA screen but with a
genome wide genetic suppressor element (GSE) screen performed by Shtutman et.al. , to
identify the genes on which cancer cells are dependent on for their survival. This screen
identified that many cancer cell lines were dependent on COPZ1 for their survival [69].
COPZ1 gene encodes for the ζ subunit of the COP1 coatomer complex [72]. An isoform
of this subunit is encoded by COPZ2 gene. Further analysis determined that this
dependence on COPZ1 by cancer cells is due the downregulation of COPZ2 gene in various
cancer cell lines. In normal cells, the loss of COPZ1 is not detrimental as COPZ2 gene
compensates for the loss and ensures continued COP1 function. However, in various cancer
cell lines, COPZ2 is downregulated and ζ2 isoform is not produced to compensate for the
loss, causing cancer cells to be dependent on ζ1 for continued COPI function. This
determined that this dependence on COPZ1 is not a classic ‘oncogene addiction’
phenomenon. Instead, the authors called it ‘isoform addiction’. A high level of COPZ2
expression is not detrimental to tumor growth indicating that COPZ2 is not a tumor
suppressor[69]. Both COPZ1 and COPZ2 genes encode precursors for miR148b and
miR152 within their introns. As discussed earlier, miR152 has been shown to have tumor
suppressor activity, indicating the most plausible reason for COPZ2 downregulation.
As shown in Figure 1.1, COPZ2 expression is downregulated in breast (MDAMB231), fibrosarcoma (HT1080) and prostate (PC3) cancer cell lines when compared to a
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normal fibroblast cell line (BJ-HTERT). Biogenesis of intronic miRNA indicate that
miRNA transcript is derived from the host transcript [24, 25]. MiRNA micro array
expression profiling has revealed that the expression of an miRNA correlates with the
expression of its host gene[21]. In concert with that, Shtutman et.al. have shown that
miR152 expression correlates with the expression of COPZ2 (Figure 1.2). Analysis of
microarray data from GEO database revealed that COPZ2 was strongly downregulated in
metastatic prostate cancer and melanoma when compared to their respective benign tumors
[69]. This indicates a similar expression pattern for miR152.
Members of the miR148/152 family have the same seed sequence, suggesting that
they play a similar biological role in cancer progression. Decreased expression on miR152
in advanced stage tumors and with a number of predicted targets being involved in EMT
indicates a possible role for this miRNA family in EMT. We have used prostate cancer
model for the experiments here with a hope of extending these results to other carcinoma
types in the future.
1.4.1 Hypothesis and Specific Aims
Hypothesis: Members of miR148/152 family inhibit cancer progression and are hence
downregulated in cancer.
Specific Aim 1: To discover novel targets of miR148/152 family with a possible role in
cancer progression. (Chapter 2)
Specific Aim 2: To analyze the possible biological role of Mir148/152 family in cancer
progression. (Chapter 3)
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Figure 1.1: Downregulation of expression of COPZ2 in various cancer cell lines compared
to the expression of COPZ1. qRT-PCR analysis of expression of COPZ1 and COPZ2 genes
in various tumor cell lines and BJ-hTERT fibroblasts. Expression is normalized using
GAPDH and is presented relative to expression in BJ-hTERT cell line.

Figure 1.2: Expression of COPZ2, and miR-152 in human tumor cell lines. Expression is
presented relative to BJhTERT. (Adapted from Shtutman et.al., 2010 [69])
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CHAPTER 2
NOVEL TARGETS OF MIRNA 148/152 FAMILY

2.1 INTRODUCTION
A single miRNA has multiple targets which regulate different regulatory pathways
depending on the mRNA population of the cell at a given time[15]. A number of targets
have been investigated and validated for miR148/152 family in different cancers [12-22].
Due to the predicted involvement of this family in the regulation of EMT, we have decided
to look for novel targets that are involved in EMT. This led to a list of genes that are not
only important for EMT but also for other cellular functions; ARHGEF12 or LARG,
LTBP1 and PAI1 (SERPINE1) [73-94].
LTBP1 gene codes for latent transforming growth factor - beta binding protein 1.
It is required for αvβ6-mediated TGF-β activation, one of the three activation mechanisms
of TGFb [73-76]. LTBP1 has been shown to play a role in cancer progression mostly via
the stromal cells or extracellular matrix [77, 78]. LTBP1, being a modulator of TGFb levels
and activity, plays a role in TGFb mediated EMT [79, 80].
SERPINE1 gene encodes for Plasminogen activator inhibitor-1 also known
as endothelial plasminogen activator inhibitor or serpin E1 protein. PAI-1 is a serine
protease inhibitor which principally inhibits tissue-type plasminogen activator (tPA) and
urokinase-type plasminogen activator (uPA), which are key enzymes for the initiation of
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fibrinolysis [81]. PAI-1 not only regulates the lysis of blood clots, but also a wide variety
of biological reactions occurring in extracellular matrices such as tumor metastasis,
neovascularization, inflammation, and cell migration[82]. TGFb induced EMT was
inhibited upon the introduction of PAI1-siRNA indicating a role for PAI1 in the
progression of EMT[83]. Decrease in PAI1 levels correlates with reduced epithelial cell
migration and tumor progression [84-86].
LARG gene codes for Rho guanine nucleotide exchange factor 12 protein.
Like other Rho GTPase proteins, it has functions in a number of cellular processes. In
contrary to other targets of the miR148a/152 family, LARG has been shown to be a tumor
suppressor gene in breast and colorectal cancers[87].
Rictor codes for Rapamycin-insensitive companion of mTOR protein. RICTOR is
a component of the mTOR-containing complex, mTORC2, which directly regulates the
phosphorylation of Akt, which mediates a variety of biological responses including cell
growth, proliferation and survival [88, 89]. RICTOR has been shown to be upregulated in
various cancers [90-92]. Increased RICTOR expression has been shown to be associated
with EMT [93, 94].
2.2. MATERIALS AND METHODS
2.2.1 Cell lines
Two different prostate cancer cell lines were used in this study, DU145 and PC3. Four
stable cell lines each of PC3 and DU145, overexpressing the pre- MiRNAs 148a, 148b,
152 and a cell line with empty vector control were established using lentiviral infection in
Dr. Shtutman’s lab. The plasmids carrying the respective microRNA also have an insert
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for Green Fluorescent Protein and the cells are sorted using Fluorescence-activated Cell
Sorting to obtain a pure population of cells overexpressing the MicroRNA. The expression
of microRNA in the cell lines is then validated using qPCR. These stable cell lines will be
used for all subsequent experiments to study the role of the MicroRNA in cancer. All the
cells were grown in DMEM/High glucose medium (HyClone™) with 10% FBS serum
(Hyclone™), 1% penicillin (100 units/ml), 1% streptomycin (292 μg/ml) and glutamine (2
mM). A standard, sterile cell culture technique was used to culture the cells. Typically,
cultures grown to 70-80% confluency were used for the experiments. Cell lines were
maintained in culture for about two months before starting a fresh culture.
The normal foreskin fibroblast line, BJ-hTERT immortalized by re-expression of
the hTERT protein, along with transformed lines, BJ-ELB and BJ-ELR, which overexpress
RAS and myc, are also used in some studies. BJ fibroblasts were cultures in DMEM/High
glucose medium with 10% FBS, 2mM L-Glutamine, 10mM sodium pyruvate and 20%
medium 199.
2.2.2. Identification of targets
An initial list of genes involved in EMT was obtained from PCR microarray by
Sabiosciences TM. The genes were then individually checked for miR148a, miR148b and
miR152 binding sites using TargetScanHumanTM.
2.2.3. Cell lysis and RNA preparation
Total RNA was extracted using Trizol purification method. For a 100 mm dish,
media was aspirated and 1 ml of Trizol reagent was used scrape the cells and placed in an
Eppendorf tube. 200 µl of chloroform was added mixed and incubated for 2–3 minutes and
12

centrifuged at 12000 g for 15 min at 4°C. The aqueous layer was transferred to a fresh tube,
500 μl of isopropanol was added and incubated for 10 minutes at room temperature. The
samples were centrifuged at 12000 g for 10min at 4°C. Supernatant was discarded and the
pellet was then washed with 1 ml 75% EtOH, spun at 7500 g for 5 min. The supernatant is
removed and the pellet is dried at room temperature for 10-15 minutes. The pellet is then
resuspended in 20 – 50 μl nuclease free water and the RNA quantity and quality was
determined at 260/280 nm using a spectrophotometer (Nanodrop™ Technologies).
2.2.4. Modification and amplification of mature miRNA’s
The RNA obtained from Trizol purification was used. This method was only used
for evaluating the expression of miRNA even though the nascent mRNA is also modified
during this procedure. Mature miRNAs were first modified by the addition of a polyA
using E-PAP enzyme from NEB Inc. 1 µg of total RNA is mixed with 2 μl E-PAP buffer,
2 μl ATP and 3.5 μl E-PAP enzyme. The final volume is made up to 20 μl using nuclease
free water and incubated at 37ºC for one hour.
2.2.5. Reverse transcription
Two different reverse transcription methods were used, one for miRNA and the
other for mRNA. For miRNA, reverse transcription was performed using Bioline Tertro
cDNA synthesis kit and 20 μl of E-PAP treated RNA. For ac sample, 1 μl universal RT
primer and 1 μl dNTP mix was added and incubated at 65ºC for 10 minutes and on ice for
2 minutes. Then, 4 μl 5X RT buffer, 1 μl RNAse inhibitor and 1 μl reverse transcriptase
were added and incubated at 45ºC for 60 minutes and at 70ºC for 15 minutes. The final
product is the diluted 1:10 and used for qPCR.
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Maxima First Strand cDNA Synthesis Kits for RT-qPCR was used for reverse
transcription of mRNA. For each sample, 2 μl of the 5X reaction mix and 1 μl Maxima™
enzyme mix is added and made up to 20 μl using nuclease free water. The samples are then
placed in a thermal cycler to be incubated at 25ºC for 10 minutes, 50ºC for 30 minutes and
85ºC for 5 minutes. The reaction is then diluted 1:10 and used for RT-PCR or qRT-PCR
or stored at -20ºC for short term storage.
2.2.6. RT-PCR:
Primers are designed using NCBI primer blast and ordered from IDT. They are
diluted to 100 μM and stored at -20ºC. Primer mixes containing both forward and reverse
primers are made with the concentration of each primer being 10 μM. The cDNA generated
from reverse transcription is used for PCR. The experiment in performed in duplicates
using Promega™ PCR master mix. For each sample, 12.5 μl master mix, 5 μl cDNA, 2.5
μl nuclease free water and 5 μl primer mix is added. The samples are then subjected to
initial denaturation (95ºC for 2 minutes) and 25 cycles of denaturation (95ºC for 45
seconds), annealing (55ºC for 45 seconds) and extension(75ºC for 20 seconds) followed by
final extension (75ºC for 5 minutes). The samples are then run on a 2% agarose gel and
bands are visualized using Enduro™ Gel Documentation System. ImageJ™ is used to
quantify the bands. Expression levels are normalized to GAPDH expression. Primers and
their sequences are listed in Table 2.1.
2.2.7 qRT-PCR:
The reactions are performed in quadruplicates in a 384 well plate using SYBR
Green PCR master mix. For each reaction, 0.5 μl of primer mix, 5 μl SYBR Green and 4.5
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μl cDNA was added. Applied Biosystems 7900 HT Fast Real Time PCR system was used
for quantification and amplification. Expression levels are normalized to house-keeping
genes, GAPDH or RPL13A.
2.2.8 Statistical Analysis:
Differences between the groups was compared using two-tailed paired student's t
test. Family-wise error rate was corrected using Bonferroni correction. P-value less than
0.05 was considered statistically significant.
2.3. RESULTS
2.3.1 Putative targets of miRNA148/152 family
A list of putative targets was obtained with the help of Sabioscience™s’ database
and Targetscan™. Concurrent with the hypothesis that miR148/152 family plays a role in
EMT, various genes involved in EMT were blasted for probable binding sites of miR148a,
miR148b and miR152. Targetscan’s ability for target prediction was evaluated by first
looking for the binding sites of the validated target of this family, DNMT1 and RICTOR.
Owing to the similarity in their sequences, it was expected that possible targets will show
binding sequences to more than one miRNA belonging to this family. Consistently, it has
been observed that the targets had binding sequences for all three miRNA belonging to
miR148/152 family. Three novel targets have been identified using this protocol; LARG,
LTBP1 and PAI-1 (SERPINE1) (Figure 2.1). Though RICTOR was only validated as a
target of miR152, TargetScan™ predicted it as a putative target for the other two miRNA
in this family.
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2.3.2 Validation of putative targets
Potential targets were validated using RT-PCR and qRT-PCR in the eight stable
cell lines (Figures 2.2); DU145 and PC3 cell lines each overexpressing one of the miRNAs
of miR148/152 family or the control miRNA. DNMT1, being a validated target, was used
as a positive control (Figure 2.3-2.4). Accordingly, DNMT1 was downregulated in all the
cell lines, albeit to a different level. Expression of DNMT1 was also evaluated in a series
of BJ cell lines; BJhTERT, a normal immortalized cell line, BJ-ELB, partially transformed
cell line and BJ-ELR, a fully transformed cell line. These cell lines have decreasing COPZ2
levels in the order of increasing tumorigenecity, suggesting decreasing levels of miR152.
Figure 2.4 shows the increase in the expression of DNMT1 in the same order. RICTOR,
which is a validated target of miR152, was downregulated in both PC3 and DU145 cell
lines overexpressing miR152. Interestingly, RICTOR was also downregulated with the
overexpression of the other two miRNAs (Figure 2.5). Two of the predicted targets, LTBP1
and LARG, are also downregulated in all the cell lines (Figures 2.6, 2.7). PAI-1, another
potential target was downregulated in all the cell lines, except the PC3 cell line
overexpressing miR148b (Figure 2.8).
2.4 Discussion
DNMT1, a DNA methylase, is an important validated target of miR148a and miR152. It
has also been shown that there is inverse correlation between the expression of DNMT1
and miR148a/miR152 (Figure2.4) and that DNMT1 hypermethylates and thereby silences
miR148a and miR152 [95]. miR148b has been shown to be silenced as a result of
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hypermethylation of the promoter region in pancreatic cancer [45] and a number of
metastatic cancers.The reintroduction of miR148a into the cancer cells with epigenetic
inactivation inhibited their motility, reduced tumor growth, and inhibited metastasis
formation in xenograft models [96]. Hypermethylation of the CpG islands in the promoter
region of miR152 by DNMT1 has been shown to be responsible for the silencing of
miR152 in endometrial cancer [47] and it has been associated with poor clinical outcome
in acute lymphoblastic leukemia (AML) [97]. Increased DNA methylation of miR148a and
miR152 promoter regions has been found in colorectal, gastric and endometrial carcinomas
when compared to the normal tissues [98].
Any alteration in the methylation pattern has been shown to accompany the process
of tumorigenesis be it hypomethylation or hypermethylation [96, 99]. Gene expression
profiling of breast cancer model system suggested that there was DNA hypermethylation
silenced a number of genes involved in cell adhesion and tight junction formation; CDH1
(E-cadherin), CGN, and CLDN4, in basal breast cancer cells that have undergone EMT.
Furthermore, it has been suggested that TGFβ-Smad2 signaling and DNMT1 form a
positive regulatory loop to maintain epigenetic silencing during epithelial to mesenchymal
transition [100]. Comparison of the gene expression profiles between invasive
mesenchymal-like MIII cells and the noninvasive epithelial MII cells revealed relatively
high expression levels of the downstream targets of TGFβ signaling, such as MMP2,
SERPINE1, and TGFβI, in MIII cells. Furthermore, expression of TGFβ1 and the TGFβactivating proteins LTBP1, LTBP2, LTBP3, LTBP4, and THBS1 was also dramatically
increased in MIII compared with MII cells [100].

17

Transforming growth factor-beta (TGF-beta) is a multifunctional regulatory
cytokine that controls many aspects of cellular function. One of the biological effects of
TGF-beta is the inhibition of proliferation of most normal epithelial cells and this suggests
a tumor suppressor role for TGF-beta. During the early phase of epithelial tumorigenesis,
TGF-beta inhibits primary tumor development and growth by inducing cell cycle arrest
and apoptosis via SMAD signaling. In later stages of tumor progression when tumor cells
become resistant to growth inhibition by TGF-beta, due to inactivation of the TGF-beta
signaling pathway or aberrant regulation of the cell cycle, the role of TGF-beta becomes
the one of tumor promotion. TGFβ overexpression along with increased nuclear phosphoSmad2 has been observed in advanced tumors [101], and Smad2 has been shown to be
involved in the EMT process [102]. To understand if miR152 has any influence on TGFβ
signaling, we performed a preliminary experiment where we tested the effect of miR152
overexpression on p-samd2/3 levels upon TGFβ treatment in DU145 cells. DU145 cells
overexpressing miR152 showed decreased induction of p-smad2/3 signaling (Figure A.1
in appendix A). Further experiments with the miR148b and miR148a need to be done to
assess the effect of miR148/152 family on TGFβ signaling.
LTBP1 expression negatively correlates with the expression of miR148/152 family
(Figure 2.5). PAI-1 expression is significantly decreased in all tested cell lines except
miR148b overexpressing PC3 cell lines (Figure 2.6), where surprisingly, it is elevated.
Also, PC3 cell lines have endogenous miR148b and overexpression might not have
changed the expression pattern.

LTBP1 regulates the bioavailability of TGFβ and

downregulation could result in decreased TGFβ activity. PAI-I and RICTOR, downstream
targets of TGFβ signaling, could have decreased levels of expression as a result. RICTOR

18

has been shown to be induced by TGFβ during TGFβ mediated EMT, upon which it pairs
with ILK, a key intracellular mediator of EMT [93].
Western blots for potential targets can indicate the effect of the miRNA148a/152
family on the protein levels of the potential targets. No conclusion can be made about the
targets until a luciferase assay is performed where the potential miRNA binding region is
deleted from the promoter and effect on expression is assayed. DNMT1, LTBP1, PAI-1
and RICTOR play a role in epithelial to mesenchymal transition. At least three of these
targets are associated with TGFβ, which is an important driver of EMT. This suggests a
role for miR148/152 family in EMT suppression.
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Table 2.1: Primer sequences for RT-PCR and qRT-PCR of the indicated genes

Gene

Sense

Antisense

GAPDH

CCCCGGTTTCTATAAATTGAGCC

ACCAGAGTTAAAAGCAGCCC

RPL13a

AGATGGCGGAGGTGCAG

GGCCCAGCAGTACCTGTTTA

Universal RT

AACGAGACGACGACAGACTTT

GAPDH

CCATGTAGACCCCTTGAAGA

miR148a

GTGCACTACAGAACTTT

miR148b

TCAGTGCATCACAGAACTTT

miR152

TCAGTGCATGACAGAACTTT

DNMT1

TGTCCCAAGAAGAGCAACGG

AGAGCAGGTTGATGTCTGCG

RICTOR

CGCTCTCTGAAGAACCTCCG

TTGATACTCCCTGCAATCTGGC

LTBP1

AACAAGGCAGGCAAGTTGTG

TCTGACATGGCGGAACACAG

LARG

ACACAGTCTACTATCACCGACA

TGCAATGCGCTCAACTTTCTG

AGAGCGCTGTCAAGAAGACC

ACGTAGGATGGGGGATGGTG

PAI-1

Table 2.2 Summary of targets
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Figures
a)
Arhgef12(LARG): Binding site – 1153-1160
5' ...UUUGACUCUAAUUUUUGCACUGA...
| | |
| | | | | | |
3' GGUUCAAGACAGU-----ACGUGACU

b)
LTBP1: Binding site: 34-40
5' ... UAAGCCCAUAUACUCUGCACUGU...
| | | | | | |
3'
GGUUCAAGACAGUACGUGACU
c)
SERPINE1: Binding site – 1657-1663
5' ...UUUCUUUUUUGAUUUUGCACUGG...
| | | | | | |
3'
GGUUCAAGACAGUACGUGACU

d)
RICTOR: Binding sites – 269-275, 1631-1637
5' ...GUAUGCAAGAGCCAAGCACUGAA...
| | | | | | |
3'
GGUUCAAGACAGUACGUGACU
5' ...UGAAUUGUUCUUAUGUGCACUGU...
| | | | |
| | | | | | |
3'
GGUUCAAGACAGUACGUGACU

Figure 2.1 miR148/152 binding sites of putative targets. An initial list of genes involved in
EMT was obtained from PCR microarray by Sabiosciences TM. The genes were then
individually checked for miRNA 152 binding sites using TargetScanHumanTM.
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Figure2.2 Expression of miR148a, miR148b and miR152 in a) PC3 and b) DU145 stable
cell lines overexpressing individual members of miR148/152 family. qPCR data is
normalized to RNU6 and represented as mean of expression and ± SD.
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Figure 2.3. Mir148/152 family downregulates the expression of DNMT1 in PC3 cell lines.
Expression of DNMT1 in stable cell lines is verified by a) qRT-PCR and b) RT-PCR.
RPL13A and GAPDH were used for normalization of qPCR and PCR data respectively. *
indicates significant downregulation (P<0.05) of DNMT1 in miRNA overexpressing cell
lines when compared to the control cell line.
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Figure 2.4 DNMT1 expression inversely correlates with COPZ2 expression. The qPCR
expression data from transformed cell lines, BJ-ELB and BJ-ELR is shown relative to
normal fibroblast cell line, BJhTERT; mean and ± SD is represented here.
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Cell Line
Figure 2.5 MiR152 downregulated the expression of RICTOR. Expression of RICTOR in
stable cell lines is verified by a) qRT-PCR and b) RT-PCR. RPL13A and GAPDH were
used for normalization of qPCR and PCR data respectively. * indicates significant
downregulation (P<0.05) of RICTOR in miRNA overexpressing cell lines when compared
to the control cell line.
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Figure 2.6 Mir148/152 family downregulated the expression of LTBP1 in PC3 cell lines.
Expression of LTBP1 in stable cell lines is verified by a) qRT-PCR and b) RT-PCR.
RPL13A and GAPDH were used for normalization of qPCR and PCR data respectively. *
indicates significant downregulation (P<0.05) of LTBP1 in miRNA overexpressing cell
lines when compared to the control cell line.
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LARG
1.20E-06
1.00E-06
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Figure 2.7 Mir148/52 family downregulated the expression of LARG in PC3 cell lines.
Expression of LARG in stable cell lines is verified by qRT-PCR. RPL13A was used for
normalization of qPCR data. * indicates significant downregulation (P<0.05) of LARG in
miRNA overexpressing cell lines when compared to the control cell line.
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Figure 2.8 Mir148a and miR152 downregulate the expression of PAI1. There is increased
expression in PC3_miR148b cell lines. Expression of PAI1 in stable cell lines is verified
by qRT-PCR. RPL13A was used for normalization of qPCR data. * indicates significant
downregulation (P<0.05) of PAI1 in miRNA overexpressing cell lines when compared to
the control cell line.
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CHAPTER 3
ROLE OF MIRNA 148/152 FAMILY ON EMT

2.1 INTRODUCTION
Metastasis is associated with poor prognosis and recurrence of malignancy.
Epithelial to mesenchymal transition has been shown to play an important role in
metastasis[103]. When undergoing the process of EMT, the epithelial cells lose their
characteristic differentiated properties like cell–cell adhesion, planar and apical–basal
polarity, and lack of motility, and acquire mesenchymal features, including motility,
invasiveness and an increased resistance to apoptosis[11, 104]. The process of EMT is
associated with changes in the mRNA and protein levels of many genes that are associated
with morphological changes. For example, there is decreased expression of E - cadherin,
an epithelial cell-cell adhesion molecule and increased expression on N - cadherin, which
plays a role in adhesion to endothelial cells[11, 105]. A number of transcription factors
regulate the expression of such genes.
To evaluate the role of miRNA 148/152 family in EMT, we studied the migratory
and adhesive capabilities of the cell and also the expression levels of important
transcription factors involved in EMT – SNAI1, SNAI2, TWIST1 and ZEB. We have also
looked at E-cadherin expression levels to investigate one of the morphological changes
accompanying EMT. E-Cadherin is downregulated by all the transcriptional factors
mentioned above
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SNAI1 (SNAIL) and SNAI2 (SLUG) belong to the Snail family of zinc-finger
transcription factors[106]. The amino terminus contains SNAG (Snail/Gfi) domain which
causes transcriptional repression. The zinc fingers mediate binding to the DNA promoters
containing the E-box sequence (CAGGTG) and facilitating transcriptional repression or
activation[107]. Apart from E-cadherin, SNAI1 also down-regulates the expression of
other epithelial molecules, like Claudins, Occludins and Muc1 and induces the expression
of genes associated with a mesenchymal and invasive phenotype, such as fibronectin and
MMP9[107].
TWIST-1 is a highly conserved transcription factor that belongs to the family of
basic helix–loop–helix (bHLH) proteins[108]. Twist-1 also binds to the DNA promoters
containing E-box domain and is involved in the regulation of genes involved in cell
proliferation and migration, like, Tbx20, Sema3C, Gadd45a, and Rab39b[109]. ZEB1 is a
member of the zinc-finger E-box-binding homeobox factor (ZEB) family and binds to the
same consensus sequence as the other three transcription factors. Apart from E-cadherin,
ZEB1 is also involved in the repression of other epithelial components like Crumbs 3 and
PATJ (Pals-1 associated tight junction protein)[95].
2.2. MATERIALS AND METHODS
2.2.1 Cell Lines
Cell lines described in Chapter 2 were used.
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2.2.2 PCR/qPCR
Methods described in the materials and methods section of Chapter 2 were used for
RNA purification, reverse transcription, PCR and qPCR.
2.2.3 Wound Healing Assay
Control and test cell lines were grown to >90% confluency in duplicates in a 12
well dish. A scratch was made using a 20 µl pipette tip. A line was drawn to mark the area
for photographs. Olympus IX81 microscope was used to take phase contrast photographs
at 10x at regular intervals.
2.2.4 Trans-well migration Assay
Corning 24 well plates with trans-wells are used for this experiment. The transwells are coated with of one of the three ECM components; collagen, fibronectin and
laminin diluted in serum-free media. This is done by incubating the plates with 10µ mg/ml
ECM component on the either side of the well for 2 hours at 37ºC. The wells are then
washed with 1X PBS and stored at 4ºC or used for experiment immediately. Upon
trypsinization, cells are washed with serum-free media and counted. Depending on the
experiment, 20,000 or 40,000 cells are plated onto the upper chamber in 100 µl of serum
free media. Media with 10% FBS is placed in the lower chamber to act as a chemoattractant. 100pm TGFβ was added to the wells when required to assess its influence on
the migration. The plates were incubated at 37ºC overnight. One of the two following
methods was used to quantify the number of migrated cells; 1. The migrated cells are fixed
in methanol and stained with eosin Y and methylene blue. The filters are mounted onto a
slide, photographed and cells are counted using Cell counter plugin in Image J software. 2.
30

Migrated cells are fixed onto the filter using 4% paraformaldehyde and stained with
2mg/ml crystal violet. Crystal violet was solubilized in 2% SDS and the intensity was read
at 595nm using Synergy™ microplate reader. A filter which was subjected to a similar
treatment but with no cells were added was used as a blank.
2.2.5 Adhesion Assay
Adhesion assay is performed in 96 well plates in triplicates. Wells are coated with
10 µg/ml collagen diluted in serum-free media for one hour and blocked with 5% Bovine
Serum Albumin) BSA in PBS for 45 minutes. 5% BSA in PBS was used as control to
account for the background adhesion. Cells are detached from the plate using 0.5M EDTA
and washed in serum free media and 40,000 cells in 50 µl serum free media are plated onto
the collagen coated and BSA blocked wells. This assay was performed for three time
points; 15 minute, 30 minute and 60 minute. After the required amount of time, media is
removed and cells are fixed with 4% paraformaldehyde, stained with crystal violet and
washed. Crystal violet was solubilized in 2% SDS and the intensity was read at 595nm
using Synergy microplate reader. Two blanks, one each for coated and uncoated wells were
used.
2.3 RESULTS
2.3.1 Effect of miR148/152 family on migration
EMT is characterized by increased migratory capabilities of the transformed cells.
In vitro migration assays were performed on DU145 and PC3 cells overexpressing
individual members of miR148/152 family. Since this study was first started to understand
the role of miR152 in tumor progression, initial assays were performed only using DU145
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cells overexpressing miR152. Scratch assay performed using DU145_miR152 cells did not
show any significant difference in the rate of wound closure (Figure 3.1). Single cell
migration through ECM component, collagen showed significant decrease in migration,
while migration in the absence of an ECM component or through fibronectin and laminin
did not show any remarkable difference (Figure 3.2). All three miRNA caused decreased
migration in DU145 cell lines while in PC3 cell lines, miR148a showed little change in the
migration rate (Figure 3.3).
Results from chapter 1 led to a theory that miR148/152 family plays a role in the
suppression of TGFβ induced EMT. To this end, we have performed preliminary studies
where trans-well migration was accompanied by TGFβ treatment of the cells. External
compensation of TGFβ caused increase in the migration rate of all the cell lines and the
percentage of increase was in lieu with the increase in the control cell lines (Figure 3.3).
2.3.2 Effect of miR148/152 family on adhesion
During EMT, cells lose their adhesive properties to detach from the basement
membrane and surrounding cells. To verify the effect of miR148/152 family on adhesive
properties of the cells, adhesion assay using collagen coated wells was performed in the
DU145 stable cell lines. All three miRNA resulted in increased adhesion of the DU145
cells (Figure 3.4). Further studies need to be done with varying concentrations of collagen,
and also in the presence of other ECM components. All the experiments need to be repeated
using PC3 cell lines before arriving at a conclusion.
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2.3.3 Effect of miR148/152 family on the expression of EMT related genes
The expression of various transcription factors that play an important role in
induction and progression of EMT and E-Cadherin, cell-cell adhesion molecule, was
studied using qRT-PCR. None of these genes is consistently up or downregulated in both
PC3 and DU145 cell lines. ZEB1 was downregulated in PC3 cell lines (Figure 3.6) while
SLUG was downregulated in DU145 cell lines (Figure 3.7). E-cadherin being the target of
all these transcription factors, is expected to be downregulated in these cell lines.
Surprisingly, E-cadherin is downregulated in DU145 cell lines and upregulated in PC3 cell
lines. However, western blot for the protein levels of E-cadherin revealed no significant
difference in the protein levels. Since, mRNA expression levels of these genes do not give
a clear indication of their expression levels, further analysis of their protein levels needs to
be performed to make any tangible conclusions.
2.4 DISCUSSION
Cell proliferation, migration, invasion and decreased adhesion are the common
characteristics of metastatic cells. Two types of migration assays are performed here.
Scratch assay represents collective cell migration that typically occurs in the tissues while,
trans-well migration assay characterizes single cell migration, and to an extent, invasion.
However, the results of both these assays can be influenced by cell proliferation in addition
to migration. Previously, MiR152 and miR148a has been shown to have an impact on cell
proliferation [43, 69]. Migration through collagen coated filter for a shorter time point of
6 hours did not show a significant difference in the migration rate of DU145 cells
overexpressing miR152. The migration assays, when performed under the influence of an
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anti-proliferative agent like Mitomycin-C can determine if the migratory effect seen here
is due to migration. Dose dependent adhesion assays using different concentrations of
collagen can strengthen the conclusion that miR148/152 family increases the adhesion of
the cells to collagen. There was decreased in the expression of SLUG and ZEB1 as shown
by the qPCR data in all the cell lines. However, analysis of protein levels of all
transcriptions factors, SNAIL, SLUG, TWIST1 and ZEB1 along with the study of nuclear
localization of these factors would provide a better understanding of the effect of
miR148/152 family on the regulation of EMT.
PC3 is an E -cadherin null cell line [110, 111] and overexpression of miR148a and
miR152 seems to increase E-cadherin levels while miR148b expression results in
decreased E-cadherin levels. E-cadherin expression in DU145 cell lines is an anomaly in
this study. While qPCR shows decreased mRNA levels, there is no significant change in
the protein levels. Due to the lack of correlation between mRNA and protein levels, it is
difficult to come to a conclusion. However, it has been shown that in DU145 cells, Pcadherin, and not E-cadherin is important for maintaining adherens junctions. Also, the
depletion of any of the cadherin-associated proteins like p120ctn, ß-catenin or α-catenin,
is sufficient to disrupt adherens junctions in DU145 cells and increase migration and cancer
cell invasion [112]. Analysis of the protein levels of the aforementioned proteins can give
a better understanding of the change in migration rate caused by miR148/152 family.
2.5 CONCLUSION AND FUTURE STUDIES
LTBP1 and LARG are potential new and common targets of all the members of the
miR148/152 family. RICTOR has been validated as a target of miR152 but it is a possible
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new target of miR148a and miR148b. PAI1 has not shown consistent downregulation with
both DU145 and PC3 cell lines overexpressing miR148b. Therefore, PAI1 can be a
potential new target of miR148a and miR152, if not miR148b. PAI1 plays an important
role in the regulation of MMP10 mediated collagen remodeling to facilitate migration and
invasion. Absence or downregulation of PAI1 expression results in decreased migration.
Further studies to investigate the role of miR148/152 family on invasion through collagen
mediated by MMP10 would provide conclusive results. RICTOR is a validated target of
miR152 and can be a potential target of miR148a.
The expression pattern and validated targets of miR148a and miR152 are very
similar. MiR148b and miR152 are both located in the genes (COPZ1 and COPZ2) coding
for the isoforms, of same protein (ϛ subunit) and are probably regulated along with the
protein coding gene, it is necessary to express one of the two miRNA for the survival. It
can be speculated that COPZ1 gene evolved to compensate for the down regulation of
COPZ2 gene. It is possible that the expression level of the members of miR148/152 family
as a whole has an impact on the target regulation and biological role and could be
functioning as a rheostat.
There is decreased single cell migration with the overexpression of miRNAs, while
there was no effect on collective cell migration as seen by the scratch assay results. Also,
there is increased adhesion to collagen matrix. Cell lines that express two or more of these
miRNA can be used to perform knockdown studies which would provide better
understanding of the role of endogenous miRNA. In-vivo metastasis studies can be
performed to further characterize the anti-metastatic effects of miR148/152 family and also
to explore their potential as replacement miRNA for cancer therapy.
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Table 3.1 Primer sequences for qRT-PCR of the indicated genes

Gene

Sense

Antisense

GAPDH

CCCCGGTTTCTATAAATTGAGCC

ACCAGAGTTAAAAGCAGCCC

RPL13a

AGATGGCGGAGGTGCAG

GGCCCAGCAGTACCTGTTTA

E-Cadherin

GATAATCCTCCGATCTTCAATCCC

CAATATGGTGTATACAGCCTCCC

SNAI1

TCGGAAGCCTAACTACAGCGA

AGATGAGCATTGGCAGCGAG

SNAI2

TGTGACAAGGAATATGTGAGCC

TGAGCCCTCAGATTTGACCTG

TWIST1

GCGTCCCACTAGCAGGC

AAGTGCGCCCCACGC

ZEB1

AAGGGCAAGAAATCCTGGGG

TCTGGTCCTCTTCAGGTGCC

Table 3.2 Summary of EMT genes
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Figure 3.1 miR152 does not effect on the collective migration of DU145 cells. Cells were
plated in duplicates and allowed to reach ~90 – 100% confluence. After the scratch, the
plates were incubated at 37°C and pictures were taken using 10 X objective on an IX81
Olympus microscope at 0 hr and 15 hrs. a) Percentage of wound healing was then assessed
and data shown with SEM (N=2), b) representative pictures of the wound closing taken at
two different time points.
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Figure 3.2 mi152 impedes migration through collagen. a) Overnight migration through
uncoated trans-wells and trans-wells coated with individual ECM components; collagen,
fibronectin and laminin. b) Representative pictures of collagen coated trans-wells. c)
Overnight migration through collagen coated wells (N=2) d) 6 hour migration through
collagen coated wells. DU145-miR152 and DU145-miR1 cells in 100 µl serum-free media
were loaded in the upper chamber of the trans-well and 400µl serum containing media
serving as a chemoattractant was placed in the bottom chamber. After incubation at 37ºC
and the migrated cells which are attached to the filter facing the lower chamber were
stained with eosin Y and methylene blue, photographed with 10X objective and scored
using ImageJ™. * indicates significant decrease (P<0.05) of migration in miRNA
overexpressing cell lines when compared to the control cell line.
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Figure 3.3 mi148/152 family impedes migration through collagen in DU145 stable cell
lines and expgenous TGFβ treatment restores migration. Overnight migration through
trans-wells coated with collagen in a) PC3 cells b) DU145. After incubation at 37ºC and
the migrated cells which are attached to the filter were stained crystal violet, and the
intensity of the dye dissolved in SDS was read using plate reader. Migration experiment
in a similar manner was also carried out in the presence of 100 pm TGFβ. * indicates
significant decrease (P<0.05) of migration in miRNA overexpressing cell lines when
compared to the control cell line. (N=3)
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Figure 3.4 miR148/152 family increases the adhesion of DU145 cells. Adhered cells are
stained with crystal violet and the intensity of dye dissolved in SDS is measured using a
plate reader. Data is shown relative to 15 minute time point with SEM (N=3) * indicates
significant increase (P<0.05) of adhesion in miRNA overexpressing cell lines when
compared to the control cell line.
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Figure 3.5 Effect of miR148/152 family on E-cadherin expression. Though qPCR suggests
decreased E-cadherin expression in DU145 cell line (a), there is no detectable change in
the protein levels as shown by western blot. a) RPL13A is used for normalization and data
is shown relative to control cell line.
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Figure 3.6 miR152 downregulated the expression of SLUG and ZEB1 in PC3 cell lines.
Expression of Transcription factors in stable cell lines is verified by qRT-PCR. RPL13A
was used for normalization of qPCR data. * indicates significant downregulation (P<0.05)
of transcription factors in miRNA overexpressing cell lines when compared to the control
cell line.
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Figure 3.7 Mir148a/152 family downregulated the expression of SLUG in DU145 cell
lines. Expression Of the transcription factors in stable cell lines is verified by qRT-PCR.
RPL13A was used for normalization of qPCR data. * indicates significant downregulation
(P<0.05) of transcription factors in miRNA overexpressing cell lines when compared to
the control cell line.
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Figure 3.8 Probable model for the effect of miR148/152 family on cancer progression.
miR152 family impedes TGFβ mediated EMT. By downregulating one or more genes
associated with TGFβ, directly or indirectly, miR148/152 family causes decrease in the
metastatic/mesenchymal characteristics like migration and invasion and increase in the
epithelial characteristics like adhesion.
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APPENDIX A

Normalized induction
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Figure A.1. Effect of miR152 on TGFβ signaling. Cells were serum starved overnight and
treated with 100pm TGFβ for indicated time points. Increase in the phosphorylated
SMAD2/3 is a direct result of exogenous TGFβ signaling. Phospho-SMAD2/3 and totalSMAD 2/3 levels from the western blot are were normalized to β -actin levels. Then, the
resultant levels of p-smad2/3 was normalized to t-SMAD2/3. MiR152 decreases the effect
of TGFβ induced pSMAD2/3 signaling.
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